FMP
BioCardia, Inc.
BCDA
NASDAQ
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
1.97 USD
0.13 (6.6%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Peter A. Altman Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.biocardia.comexchange
NASDAQ
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscl...
CIK
0000925741
ISIN
US09060U5074
CUSIP
09060U507
Address
320 Soquel Way
Phone
650 226 0120
Country
US
Employee
16
IPO Date
Nov 13, 1996
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
BCDA Financial Summary
CIK
0000925741
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
09060U507
ISIN
US09060U5074
Country
US
Price
1.97
Beta
1.27
Volume Avg.
57.52k
Market Cap
9.03M
Shares
-
52-Week
1.63-10.8
DCF
-0.27
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.49
P/B
-
Website
https://www.biocardia.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BCDA News
It looks like there's no news available.
